PROX1 and lymphatic malformation: In our data, the down-regulation of Prox1 by rapamycin did not affect the proliferation of HepG2 cells (Fig. 1a), but a recent report showed that the treatment of rapamycin in lymphatic endothelial cells of lymphatic malformations (LM-LEC) diminished cellular proliferation [28].